SCHEMBL17287703

SCHEMBL17287703

COc1cccc(CC(=O)Nc2nc3ccc(C(F)(F)F)cc3s2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CSNK1D P48730 19/20 1.00
▸ WNT3A P56704 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17287839 0.89 CSNK1D (1.00) CSNK1DWNT3A
SCHEMBL17287824 0.89 CSNK1D (1.00) CSNK1DWNT3A
SCHEMBL17287650 0.89 CSNK1D (1.00) CSNK1D
SCHEMBL17287767 0.85 CSNK1D (1.00) CSNK1D
SCHEMBL17287559 0.85 CSNK1D (1.00) CSNK1D
SCHEMBL17287855 0.83 CSNK1D (1.00) CSNK1D
SCHEMBL17287812 0.83 CSNK1D (1.00) CSNK1D
SCHEMBL17287645 0.83 CSNK1D (1.00) CSNK1DWNT3A
SCHEMBL17287677 0.81 CSNK1D (1.00) CSNK1D
SCHEMBL4914800 0.81 CSNK1D (0.87) CSNK1DWNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3348550-B1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES CONSEJO SUPERIOR INVESTIGACION (ES) 2019-04-24 — — EP claimed
EP-3348550-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2018-07-18 — — EP claimed
US-9592224-B2 Substituted benzothiazoles and therapeutic uses thereof for the treatment of human diseases DONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2017-03-14 — — US claimed
US-20150352082-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2015-12-10 — — US claimed
EP-2949651-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES Consejo Superior De Investigaciones Científicas (CSIC) (ES) 2015-12-02 — — EP claimed
EP-3348550-B1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES CONSEJO SUPERIOR INVESTIGACION (ES) 2019-04-24 — — EP disclosed
EP-3348550-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2018-07-18 — — EP disclosed
US-9592224-B2 Substituted benzothiazoles and therapeutic uses thereof for the treatment of human diseases DONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2017-03-14 — — US disclosed
US-20150352082-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2015-12-10 — — US disclosed
EP-2949651-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES Consejo Superior De Investigaciones Científicas (CSIC) (ES) 2015-12-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150352082-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES CSNK1A1, CRY1, CSNK1G1 CSNK1D 13/4885WNT3A 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback